SCHEDULE 13D/A: Activist Investor Zentree and Richard Magides Take 18.2% Stake in 23andMe, Demand Governance Reforms and Cost Management

Activist investors Zentree Investments Limited and Richard Magides have disclosed an 18.2% beneficial ownership in 23andMe Holding Co., advocating for minority shareholder rights, prudent cost management, and equal treatment for Class A and Class B shares.

Summary

• Zentree Investments Limited and Richard Magides collectively beneficially own 3,699,236 shares of 23andMe Holding Co.'s Class A Common Stock.
• This stake represents 18.2% of the Class A Common Stock outstanding as of March 6, 2025, which was 20,340,344 shares.
• The investors' primary purpose is to ensure fair treatment and a voice for minority investors.
• They seek to prevent the sale of 23andMe at an unreasonable price.
• They advocate for more prudent management of the company's costs.
• They appeal for Class A and Class B shares to be granted equal rights.
• They urge management to act in the best interests of all shareholders and address conflicts of interest.
• Richard Magides purchased 250,000 shares between March 26-28, 2025, at prices ranging from $0.564476 to $0.66.
• Zentree Investments Limited purchased 150,000 shares on March 26, 2025, at prices ranging from $0.540434 to $0.558558.
• Funds used for the purchases were 'Available net assets' for Zentree Investments Limited and 'Personal funds' for Richard Magides.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative for 23andMe's current operational and governance state, as an activist investor has taken a large stake specifically to address perceived issues like imprudent cost management, potential unreasonable sale price, and conflicts of interest. However, the presence of an activist could be seen as a potential catalyst for positive change, preventing a lower score.

Positives

• The emergence of an activist investor with a significant stake (18.2%) signals a strong push for corporate governance improvements and shareholder value creation.
• The stated intent to ensure fair treatment for minority investors and address conflicts of interest could benefit all shareholders.
• Advocacy for more prudent cost management could lead to improved financial efficiency for 23andMe.

Negatives

• The activist filing highlights significant concerns regarding 23andMe's current management, including potential for an 'unreasonable price' sale and 'imprudent management of costs'.
• The demand for equal rights for Class A and Class B shares indicates a perceived inequality in the current capital structure.
• The call to address 'conflicts of interest between management and investors' suggests existing governance issues.

Risks

• Risk of the company being sold at an unreasonable price, as highlighted by the activist investor.
• Risk of imprudent management of company costs, leading to inefficiencies.
• Risk of unequal rights between Class A and Class B shares, potentially disadvantaging certain shareholders.
• Risk of conflicts of interest between management and investors, which could undermine shareholder value.

Future Outlook

The reporting persons intend to actively engage with 23andMe's management to advocate for minority investor rights, prevent an unreasonable sale of the company, promote prudent cost management, and achieve equal rights for Class A and Class B shares, aiming to ensure management acts in the best interests of all shareholders and addresses conflicts of interest.

Management Comments

• "We want to ensure that minority investors are afforded a voice, thereby ensuring fair treatment."
• "We seek to prevent the sale of the company at an unreasonable price and advocate for more prudent management of the company's costs."
• "Additionally, we appeal that Class A and Class B shares be granted equal rights."
• "We urge the management to act in the best interests of all shareholders and to address any conflicts of interest between management and investors."

Industry Context

This filing represents an activist investor taking a significant stake in a genomics and biotechnology company, 23andMe, which operates in a rapidly evolving and capital-intensive sector. The demands for improved cost management and corporate governance reflect broader investor scrutiny on profitability and shareholder alignment within the biotech industry, especially for companies that have seen significant valuation shifts.

Corporate Governance

Stakeholder Impact

• Shareholders (especially minority and Class A shareholders): Potential for improved corporate governance, fair treatment, and increased shareholder value if the activist's demands are met. Class A shareholders could benefit from equal rights with Class B shares.
• Management: Will face increased scrutiny and pressure to address the concerns raised by the activist investor regarding cost management, potential sale price, and conflicts of interest.

Next Steps

• The reporting persons will continue to engage with 23andMe's management and potentially other shareholders to advocate for their stated objectives.
• 23andMe's management may respond to the activist's demands, potentially leading to discussions, negotiations, or changes in corporate strategy or governance.

Key Dates

Recommendation

Keywords

23andMe Holding Co., Zentree Investments Limited, Richard Magides, Activist Investor, Shareholder Rights, Corporate Governance, Cost Management, Class A Common Stock, Class B Shares, SEC Filing, Schedule 13D, Minority Shareholders